Table 3.

Efficacy of the quadrivalent vaccine in preventing external genital lesions and AIN (per-protocol population)

	Giuliano [67]	Palefsky [71]	Goldstone [72]
Population	Per-protocol	Per-protocol	Per-protocol*
	(16–26 years)	(16–26 years)	(16–26 years)
External genital lesions	90.4%;
	(95%; CI: 69.2–98.1)
AIN		77.5%;	91.7%;
		(95%; CI: 39.6–93.3)	(95%; CI: 44.6–99.8)
Anogenital warts	89.4%;
	(95%; CI: 65.5–97.9)

* Post-hoc analysis. AIN Anal intraepithelial neoplasia.